First results of 13-valent pneumococcal conjugate vaccine treatment in patients with chronic bronchopulmonary diseases: evaluation safety and tolerability

Abstract

The data on the safety and tolerability of vaccination with the 13valent conjugated vaccine against pneumococcal infection of patients with chronic bronchopulmonary diseases is cited. Background. To evaluate the safety and tolerability of 13valent pneumococcal conjugate vaccine in patients with chronic bronchopulmonary disorders (COPD and asthma). Methods. The study involved 67 patients with chronic bronchopulmonary diseases, 33 of them had COPD (group I), and 34 had asthma (group II). Patients received 1 dose of vaccine, «Prevenar13» intramuscularly in the left shoulder. Within 7 days after vaccination all subjects filled out specially designed questionnaire, reflecting the local and general adverse events. Results. Vaccination with 13valent pneumococcal conjugate vaccine of patients with COPD or asthma was well tolerated, no serious adverse events within 7 days of postvaccination period were observed.